295 related articles for article (PubMed ID: 23636569)
21. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
22. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V
Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158
[TBL] [Abstract][Full Text] [Related]
23. Hair analysis as a tool to evaluate the prevalence of synthetic cannabinoids in different populations of drug consumers.
Salomone A; Luciano C; Di Corcia D; Gerace E; Vincenti M
Drug Test Anal; 2014; 6(1-2):126-34. PubMed ID: 24115381
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period.
Tuv SS; Krabseth H; Karinen R; Olsen KM; Øiestad EL; Vindenes V
Accid Anal Prev; 2014 Jan; 62():26-31. PubMed ID: 24129318
[TBL] [Abstract][Full Text] [Related]
25. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.
Banister SD; Stuart J; Kevin RC; Edington A; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Hibbs DE; Glass M; Connor M; McGregor IS; Kassiou M
ACS Chem Neurosci; 2015 Aug; 6(8):1445-58. PubMed ID: 25921407
[TBL] [Abstract][Full Text] [Related]
26. [Spice in France: mixed herbs containing synthetic cannabinoids].
Schlatter J; Chiadmi F; Chariot P
Ann Biol Clin (Paris); 2012; 70(4):413-22. PubMed ID: 22796613
[TBL] [Abstract][Full Text] [Related]
27. Mixed consumption of cannabis and "Spice".
Dziadosz M; Klintschar M; Teske J
Forensic Sci Int; 2014 Feb; 235():e1-2. PubMed ID: 24389330
[No Abstract] [Full Text] [Related]
28. Detection of synthetic cannabinoids in oral fluid using ELISA and LC-MS-MS.
Rodrigues WC; Catbagan P; Rana S; Wang G; Moore C
J Anal Toxicol; 2013 Oct; 37(8):526-33. PubMed ID: 23946452
[TBL] [Abstract][Full Text] [Related]
29. The role of illicit, licit, and designer drugs in the traffic in Hungary.
Institóris L; Hidvégi E; Dobos A; Sija É; Kereszty ÉM; Tajti LB; Somogyi GP; Varga T
Forensic Sci Int; 2017 Jun; 275():234-241. PubMed ID: 28412575
[TBL] [Abstract][Full Text] [Related]
30. Correlates of Marijuana Drugged Driving and Openness to Driving While High: Evidence from Colorado and Washington.
Davis KC; Allen J; Duke J; Nonnemaker J; Bradfield B; Farrelly MC; Shafer P; Novak S
PLoS One; 2016; 11(1):e0146853. PubMed ID: 26800209
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.
Hutter M; Moosmann B; Kneisel S; Auwärter V
J Mass Spectrom; 2013 Jul; 48(7):885-94. PubMed ID: 23832945
[TBL] [Abstract][Full Text] [Related]
32. Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users.
Theunissen EL; Reckweg JT; Hutten NRPW; Kuypers KPC; Toennes SW; Neukamm MA; Halter S; Ramaekers JG
Pharmacol Biochem Behav; 2021 Mar; 202():173118. PubMed ID: 33497715
[TBL] [Abstract][Full Text] [Related]
33. Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids.
Spinelli E; Barnes AJ; Young S; Castaneto MS; Martin TM; Klette KL; Huestis MA
Drug Test Anal; 2015 Jun; 7(6):467-74. PubMed ID: 25167963
[TBL] [Abstract][Full Text] [Related]
34. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.
Möller I; Wintermeyer A; Bender K; Jübner M; Thomas A; Krug O; Schänzer W; Thevis M
Drug Test Anal; 2011 Sep; 3(9):609-20. PubMed ID: 20872894
[TBL] [Abstract][Full Text] [Related]
35. Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens.
Wohlfarth A; Scheidweiler KB; Castaneto M; Gandhi AS; Desrosiers NA; Klette KL; Martin TM; Huestis MA
Clin Chem Lab Med; 2015 Feb; 53(3):423-34. PubMed ID: 25263309
[TBL] [Abstract][Full Text] [Related]
36. Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project.
Hermanns-Clausen M; Kithinji J; Spehl M; Angerer V; Franz F; Eyer F; Auwärter V
Drug Test Anal; 2016 Oct; 8(10):1030-1038. PubMed ID: 26768345
[TBL] [Abstract][Full Text] [Related]
37. LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine.
Kronstrand R; Brinkhagen L; Birath-Karlsson C; Roman M; Josefsson M
Anal Bioanal Chem; 2014 Jun; 406(15):3599-609. PubMed ID: 24424965
[TBL] [Abstract][Full Text] [Related]
38. Novel halogenated synthetic cannabinoids impair sensorimotor functions in mice.
Bilel S; Tirri M; Arfè R; Ossato A; Trapella C; Serpelloni G; Neri M; Fattore L; Marti M
Neurotoxicology; 2020 Jan; 76():17-32. PubMed ID: 31610187
[TBL] [Abstract][Full Text] [Related]
39. Highly sensitive screening and analytical characterization of synthetic cannabinoids in nine different herbal mixtures.
Alves VL; Gonçalves JL; Aguiar J; Caldeira MJ; Teixeira HM; Câmara JS
Anal Bioanal Chem; 2021 Mar; 413(8):2257-2273. PubMed ID: 33575815
[TBL] [Abstract][Full Text] [Related]
40. Spicing things up: synthetic cannabinoids.
Spaderna M; Addy PH; D'Souza DC
Psychopharmacology (Berl); 2013 Aug; 228(4):525-40. PubMed ID: 23836028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
